11 citations,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Serial trichoscopy is more reliable than the modified hair pull test for tracking alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.
Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.
70 citations,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
3 citations,
February 2019 in “Disease Markers” The index to ring finger ratio may indicate disease severity in female ankylosing spondylitis patients, but not in males.
Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.
April 2023 in “Research Square (Research Square)” Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.
April 2018 in “Journal of Investigative Dermatology” Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.
65 citations,
December 2015 in “Experimental dermatology” Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.
19 citations,
September 2010 in “Journal of the European Academy of Dermatology and Venereology” The CLASI is useful but needs revision to accurately assess all cutaneous lupus erythematosus subtypes.
Belimumab effectively controls SLE disease activity and reduces steroid use.
26 citations,
August 2013 in “Australasian Journal of Dermatology” Certain scalp patterns can indicate the severity and activity of hair loss in Turkish alopecia patients.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
1 citations,
March 2022 in “Dermatology Research and Practice” Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.
31 citations,
February 2014 in “Inflammation Research” Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.
2 citations,
March 2019 in “PubMed” A new tool helps lupus patients and doctors better track symptoms and quality of life.
1 citations,
September 2017 in “Journal of Pathology of Nepal” Testing hair roots with a special dye is a simple, non-invasive way to check disease progress in pemphigus vulgaris patients.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.
40 citations,
October 2012 in “Journal of the American Academy of Dermatology” CLASI is a valid tool for assessing skin activity and damage in lupus patients.
2 citations,
September 2023 in “JMIR. Journal of medical internet research/Journal of medical internet research” Machine learning can predict symptoms and quality of life in chronic skin disease patients using smartphone app data, and shows that app use varies with patient characteristics.
2 citations,
January 2006 in “Technical report” The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.
7 citations,
January 2009 in “Indian Journal of Dermatology Venereology and Leprology” Hair changes may indicate disease activity in pemphigus patients.
39 citations,
May 2019 in “Journal of the American Academy of Dermatology” Hair loss in lupus patients indicates higher disease activity.
January 2021 in “Turkiye Klinikleri Journal of Dermatology” The MPV/PC ratio can help assess disease activity in alopecia areata.
4 citations,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
68 citations,
April 2012 in “Digestive and Liver Disease” Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.
156 citations,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
26 citations,
September 2013 in “Journal of Dermatological Science” Serum granulysin levels can indicate the activity and prognosis of alopecia areata.